# Associate Director, Toxicology (Nonclinical Safety Evaluation) at City Therapeutics

> United States · Director+ · Other · open. Source: https://alderhq.app/jobs/greenhouse%3Acitytherapeutics%3A5232666008 (read 2026-11-22).

## Facts (observed)

- Company: [City Therapeutics](https://alderhq.app/companies/city-therapeutics)
- Location text: Cambridge, Massachusetts, United States; City Therapeutics
- Where it can be done from (inferred): United States (evidence: "Location: Cambridge, Massachusetts, United States; City Therapeutics")
- Posted: 2026-05-27 (179 days ago)
- First seen by alder: 2026-11-04 · last verified: 2026-11-19
- Reposted: 0 times · edited: 0 times
- Apply on the employer's site: https://job-boards.greenhouse.io/citytherapeutics/jobs/5232666008

## Pay and sponsorship

- Posted pay: not posted
- Market band for similar posted roles (Boston, n 389): p25 $189k, median $220k, p75 $258k

## Description (the employer's text)

City Therapeutics is a biopharmaceutical company harnessing next-generation engineering to improve and expand the reach of RNAi-based medicines. The company is building a pipeline of innovative RNAi therapeutics to make a significant impact for patients across multiple therapeutic areas. Co-founded by pioneering executives and scientists in RNAi, City Therapeutics is based in Cambridge, MA, and has raised $140 million from leading life sciences investors.

### The Role

We’re seeking an Associate Director, Nonclinical Safety Evaluation (NSE) who will play a pivotal role in overseeing and critically evaluating nonclinical safety studies across City’s RNAi therapeutic programs. This is a highly visible, hands-on role for someone who brings strong scientific judgment, deep toxicology expertise, and a sharp eye for study design, data quality, and interpretation.

You will be responsible for providing scientific oversight of outsourced nonclinical safety studies, reviewing and interpreting results, and ensuring that findings are placed in the appropriate biological and development context. Working closely with internal teams and external partners, you will help generate high-quality nonclinical safety packages that support sound decision-making and regulatory advancement.

### How You’ll Contribute

• Oversee non-GLP and GLP nonclinical safety studies across discovery and development-stage programs, with a focus on quality, execution, interpretation, and fit-for-purpose study design.

• Serve as the primary scientific reviewer for outsourced nonclinical safety studies, critically evaluating protocols, amendments, reports, and raw or interpreted data to ensure rigor, clarity, and appropriate conclusions.

• Provide expert interpretation of toxicology studies, including general toxicology, safety pharmacology, genetic toxicology, and, where applicable, reproductive toxicology and carcinogenicity findings, highlighting key results, risks, trends, and development implications.

• Identify data gaps, inconsistencies, or study conduct issues, and work with internal and external teams to resolve them efficiently and scientifically.

• Participate actively in cross-functional team meetings to communicate study progress, interpret findings, and provide nonclinical safety input to broader program discussions.

• Partner closely with Chemistry, Biology, Translational Sciences, CMC, Regulatory Affairs, Clinical Development, other relevant functions and program teams to contextualize nonclinical safety findings and support next-step recommendations.

• Contribute to the planning and monitoring of nonclinical safety studies required to support candidate progression and regulatory submissions.

• Support authoring and review of nonclinical summaries, study interpretation sections, and regulatory documents, including materials supporting IND-enabling packages.

• Represent Nonclinical Safety Evaluation in cross-functional discussions, clearly communicating study outcomes, risks, and recommendations.

• Help maintain high standards for external study oversight, documentation, data review, and reporting practices across the function.

• Stay current on evolving toxicology methods, nonclinical safety expectations, and regulatory guidance relevant to RNAi and oligonucleotide therapeutics.

### The Ideal Candidate

• PhD or DVM, or equivalent advanced degree in Toxicology, Pharmacology, Pathology, Veterinary Sciences, or a related field, with 5+ years, Masters with 7+ or a Bachelors with 10+ of relevant experience in biotech or pharmaceutical drug development, or direct experience as a Study Director at a GLP-qualified CRO.

• Strong experience overseeing outsourced nonclinical safety studies and critically reviewing protocols, data, and final reports.

• Deep expertise in the interpretation of toxicology data, including general toxicology, genetic toxicology, reproductive toxicology, carcinogenicity, and related nonclinical safety assessments, with sound scientific judgment and attention to detail.

• Strong understanding of GLP and non-GLP study conduct, study design, and reporting standards.

---
Data: alder (https://alderhq.app). Cite https://alderhq.app/jobs/greenhouse%3Acitytherapeutics%3A5232666008 and the date you read it. Observed facts come from the employer's own listing; location reach, level, family and skills are inferences.
